ghk-cu desensitization or tolerance peptide receptor downregulation Frontiers ghk-cu tolerance desensitization loss of

Thymosin Alpha-1 is frequently administered alongside other therapies

Findings were categorized into motor symptoms (such as gait disturbances and neuropathy), non-motor symptoms (focusing on cognitive decline), pathophysiological mechanisms (based on molecular pathways, neuropathology, metabolites and genes), and therapeutic implications (Vit B12 supplementation, clinical recommendations)

The peptide's antioxidant mechanism operates through activation of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, a master regulator of cellular antioxidant responses

Both peptides support tissue repair from complementary angles